Business Wire

emporia: Smartphones Now More Popular Than Landline Phones Among the Over 60s

4.9.2019 10:00:00 EEST | Business Wire | Press release

Share

Three out of four senior citizens would rather live without a conventional landline telephone than their smartphone. These are the findings of the 2019 Senior Citizens Survey: Smart Technology - Everyday, conducted by emporia Telecom in partnership with the German Senior Citizens League, in which 500 smartphone owners aged over 60 were interviewed.

Digital communication has become a simple matter of fact for many older people . One significant reason according to 83 percent of interviewees is: it is easier to maintain contact with family and friends via a smartphone.

According to the survey, three-quarters of senior citizens don’t want to be without their smartphone when they are out and about. It's also essential to them when travelling. It means that they always have useful information to hand, like weather forecasts and maps.

But it's far from every senior citizen that enjoys the benefits of the digital world. “75 million senior citizens in the EU today still don't own a smartphone. Yet there is an ever-increasing number of day-to-day activities that can only be performed with one. It's important to keep up to pace with modern communication technology so that you don’t suddenly find yourself cut adrift,” says Eveline Pupeter, owner and CEO of emporia Telecom. “It's our mission to guide older people into the digital future.”

The survey clearly identifies the concerns and difficulties experienced by senior citizens. Many older people worry about being left behind in a technology-driven world. For example, they wonder if they will even be able to perform daily errands and tasks such as using banking services, dealing with public authorities or buying bus and train tickets just as easily as they could before. “There's no stopping the progress of technology, but technology can also be simplified,” says emporia boss Eveline Pupeter. “We are seeking to gradually break down the fear of interacting with technology, and to help get the older generation up and ready for the future with user-friendly smartphones.

emporia is presenting two innovations simultaneously this September: The emporiaSMART.3 and the emporiaSMART.3mini. Despite their simplicity of use, both smartphones are fully intelligent, highly complex and state-of-the-art devices.

The emporiaSMART.3 is an easy-to-use top-class smartphone equipped with all the usual features such as two cameras, a powerful battery, Wi-Fi, Bluetooth, GPS, 5.5” screen, Type-C charging etc. It has a simple interface and mechanical home button and it’s also dust and splash-proof, compatible with hearing aids, has a sound amplifier, emergency call button, charging station and learning manual.

The SMART.3mini is something special. It was developed specially for men who wanted a compact smartphone that would easily fit into their trouser or shirt pocket. The SMART.3mini features a 4.95 inch touchscreen, meaning it's still easy to see and use. Spec-wise he mini is every bit the equal of its big brother, the SMART.

Talking about her mission, Eveline Pupeter says: “75 million of 65+ senior citizens in the EU still don't have a smartphone. It's emporia's goal to guide this generation into the digital future. Because being “smart” has nothing to do with age.”

The Linz-based manufacturer has a dual approach towards bringing digitalisation to the older generation. Its hardware and software solutions are precisely tailored for this target group. But it has also developed new training courses (such as Smartphones for Beginners, WhatsApp courses, Staying Secure on the Smartphone) to make it easier for senior citizens to get started.

emporia, the technology leader

emporia is an Austrian company that develops, manufactures and markets mobile telephones, smartphones and apps for the older generation. emporia’s products also include a wide range of accessories and landline telephones. Founded in 1991, emporia now operates in more than 30 countries around the world. The company is wholly owned by Eveline Pupeter who runs the business, together with her experienced management team. emporia employs 100 people. Its head office is located in the city of Linz on the banks of the Danube.

To view this piece of content from cts.businesswire.com, please give your consent at the top of this page.

Contact information

Walter Deil
+43 670 7010 322
deil@emporia.at

About Business Wire

For more than 50 years, Business Wire has been the global leader in press release distribution and regulatory disclosure.

Subscribe to releases from Business Wire

Subscribe to all the latest releases from Business Wire by registering your e-mail address below. You can unsubscribe at any time.

Latest releases from Business Wire

Corcept Announces CHMP Opinion Recommending EU Marketing Authorization for Lifyorli ® (Relacorilant)18.9.2026 15:00:00 EEST | Press release

Corcept Therapeutics Incorporated (NASDAQ: CORT), a commercial-stage company engaged in the discovery and development of medications to treat severe endocrinologic, oncologic, metabolic and neurologic disorders by modulating the effects of the hormone cortisol, today announced that the European Medicines Agency’s Committee for Medicinal Products for Human Use (CHMP) has recommended that the European Commission (EC) should approve relacorilant, combined with the chemotherapy drug nab-paclitaxel, for the treatment of patients with platinum-resistant ovarian cancer. The CHMP’s recommendation is based on positive data from Corcept’s Phase 2 and pivotal Phase 3 ROSELLA trials, in which patients receiving relacorilant combined with nab-paclitaxel experienced improved progression-free and overall survival compared to patients who received nab-paclitaxel alone. The safety profile of relacorilant plus nab-paclitaxel in these trials was consistent with the safety profile of nab-paclitaxel monoth

Enhertu ® Recommended for Approval in the EU by CHMP as Adjuvant Treatment for Patients with Residual Disease After Neoadjuvant Treatment for HER2 Positive Early Breast Cancer18.9.2026 15:00:00 EEST | Press release

Enhertu® (trastuzumab deruxtecan) has been recommended for approval in the European Union (EU) as a monotherapy for the adjuvant treatment of adult patients with resected HER2 positive breast cancer who have residual invasive disease after neoadjuvant taxane-based and HER2 targeted treatment. Enhertu is a specifically engineered HER2 directed DXd antibody drug conjugate (ADC) discovered by Daiichi Sankyo (TSE: 4568) and being jointly developed and commercialized by Daiichi Sankyo and AstraZeneca (LSE/STO/NYSE: AZN). The Committee for Medicinal Products for Human Use (CHMP) of the European Medicines Agency (EMA) based its positive opinion on results from the DESTINY-Breast05 phase 3 trial presented at the 2025 European Society for Medical Oncology (#ESMO25) Congress and subsequently published in The New England Journal of Medicine. The recommendation will now be reviewed by the European Commission, which has the authority to grant marketing authorizations for medicines in the EU. In DES

CHMP Recommends EU Approval of New Indication for Alfasigma’s Jyseleca ® (filgotinib), Treatment of Adults With Axial Spondyloarthritis18.9.2026 13:58:00 EEST | Press release

Alfasigma S.p.A, a global pharmaceutical company with a focus on innovation in rare disease and specialty care in areas where there is significant unmet patient need, today announced that the European Medicines Agency’s (EMA) Committee for Medicinal Products for Human Use (CHMP) has issued a positive opinion for Jyseleca® (filgotinib), an oral, once-daily JAK1 preferential inhibitor, for the treatment of patients with active axial spondyloarthritis (axSpA), both non-radiographic and radiographic forms of the disease, who have responded inadequately to conventional therapy. Following this positive opinion, the application is now referred to the European Commission (EC) for final action. The EC’s decision is expected in the next weeks. “At present, half of people living with axSpA fail to adequately respond to treatment, leaving them with years of preventable struggle with persistent pain and other impactful symptoms,” said Daniele D'Ambrosio, Chief Development Officer, Alfasigma. “This

IMPACT Therapeutics and Pharmanovia Announce Positive CHMP Opinion for Senaparib, as a Potential First-Line Maintenance Treatment of Advanced High-Grade Epithelial Ovarian, Fallopian Tube, and Primary Peritoneal Cancer18.9.2026 13:38:00 EEST | Press release

For business and medical media only This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20260918325771/en/ Stephan Eder, CEO, Pharmanovia IMPACT Therapeutics (07630.HK), a commercial-stage biotechnology company focused on the discovery and development of targeted anti-cancer therapeutics based on synthetic lethality mechanisms, together with global specialty pharmaceutical company Pharmanovia, today jointly announce that the Committee for Medicinal Products for Human Use (CHMP) of the European Medicines Agency (EMA) has adopted a positive opinion recommending the granting of a Marketing Authorisation (MA) for the medicinal product Sepalna® (senaparib) intended for the maintenance treatment of advance epithelial ovarian, fallopian tube and primary peritoneal cancer. Following the CHMP’s recommendation for approval, senaparib will be submitted to the European Commission (EC) for final decision. Once approved by the EC, senaparib will

Estithmar Holding Announces Completion of 48.68% Stake Transfer in Shahba Bank to Masaref Holding, a Subsidiary of Estithmar Capital18.9.2026 12:48:00 EEST | Press release

Estithmar Holding Q.P.S.C. announced the completion of the transfer of a 48.68% stake in Shahba Bank to Masaref Holding LLC, subsidiary of Estithmar Capital, Estithmar Holding’s financial services and investments arm. This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20260918807909/en/ Estithmar Holding Announces Completion of 48.68% Stake Transfer in Shahba Bank to Masaref Holding, a Subsidiary of Estithmar Capital (Photo: AETOSWire) As a shareholder, Masaref Holding intends to support the assessment of proposals aimed at strengthening Shahba Bank’s financial, operational and technological capabilities, including potential capital enhancement, branch network expansion, and the development of products and services for individuals, businesses and SMEs. The proposals may include modernizing banking and operational systems, develop digital services, and strengthen governance, compliance, risk management and cybersecurity to enhance

In our pressroom you can read all our latest releases, find our press contacts, images, documents and other relevant information about us.

Visit our pressroom
World GlobeA line styled icon from Orion Icon Library.HiddenA line styled icon from Orion Icon Library.Eye